• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗凋亡BCL-2蛋白在多发性骨髓瘤中的作用与调控

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma.

作者信息

Slomp Anne, Peperzak Victor

机构信息

Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

出版信息

Front Oncol. 2018 Nov 20;8:533. doi: 10.3389/fonc.2018.00533. eCollection 2018.

DOI:10.3389/fonc.2018.00533
PMID:30524962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6256118/
Abstract

Apoptosis plays a key role in protection against genomic instability and maintaining tissue homeostasis, and also shapes humoral immune responses. During generation of an antibody response, multiple rounds of B-cell expansion and selection take place in germinal centers (GC) before high antigen affinity memory B-cells and long-lived plasma cells (PC) are produced. These processes are tightly regulated by the intrinsic apoptosis pathway, and malignant transformation throughout and following the GC reaction is often characterized by apoptosis resistance. Expression of pro-survival BCL-2 family protein MCL-1 is essential for survival of malignant PC in multiple myeloma (MM). In addition, BCL-2 and BCL-XL contribute to apoptosis resistance. MCL-1, BCL-2, and BCL-XL expression is induced and maintained by signals from the bone marrow microenvironment, but overexpression can also result from genetic lesions. Since MM PC depend on these proteins for survival, inhibiting pro-survival BCL-2 proteins using novel and highly specific BH3-mimetic inhibitors is a promising strategy for treatment. This review addresses the role and regulation of pro-survival BCL-2 family proteins during healthy PC differentiation and in MM, as well as their potential as therapeutic targets.

摘要

细胞凋亡在防止基因组不稳定和维持组织稳态方面发挥着关键作用,同时也塑造体液免疫反应。在抗体反应产生过程中,生发中心(GC)会发生多轮B细胞扩增和选择,然后才产生高抗原亲和力记忆B细胞和长寿浆细胞(PC)。这些过程受到内源性凋亡途径的严格调控,而贯穿GC反应及之后的恶性转化通常以抗凋亡为特征。促生存BCL-2家族蛋白MCL-1的表达对于多发性骨髓瘤(MM)中恶性PC的存活至关重要。此外,BCL-2和BCL-XL也有助于抗凋亡。MCL-1、BCL-2和BCL-XL的表达由骨髓微环境中的信号诱导并维持,但过表达也可能由基因损伤导致。由于MM PC依赖这些蛋白存活,使用新型且高度特异性的BH3模拟抑制剂抑制促生存BCL-2蛋白是一种有前景的治疗策略。本综述探讨了促生存BCL-2家族蛋白在健康PC分化和MM中的作用及调控,以及它们作为治疗靶点的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7463/6256118/2bbead3d5886/fonc-08-00533-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7463/6256118/ec44895c4412/fonc-08-00533-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7463/6256118/2bbead3d5886/fonc-08-00533-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7463/6256118/ec44895c4412/fonc-08-00533-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7463/6256118/2bbead3d5886/fonc-08-00533-g0002.jpg

相似文献

1
Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma.抗凋亡BCL-2蛋白在多发性骨髓瘤中的作用与调控
Front Oncol. 2018 Nov 20;8:533. doi: 10.3389/fonc.2018.00533. eCollection 2018.
2
Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.通过BH3模拟物分析评估扁桃体和白血病B细胞亚群中BCL-2成员之间的功能差异。
Cell Death Differ. 2017 Jan;24(1):111-119. doi: 10.1038/cdd.2016.105. Epub 2016 Sep 30.
3
MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.在整个B细胞发育过程中都需要MCL-1,其缺失会使特定的B细胞亚群对BCL-2或BCL-XL的抑制敏感。
Cell Death Dis. 2016 Aug 25;7(8):e2345. doi: 10.1038/cddis.2016.237.
4
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.在人骨髓瘤细胞中,Mcl-1和Bcl-xL受白细胞介素-6共同调控。
Br J Haematol. 1999 Nov;107(2):392-5. doi: 10.1046/j.1365-2141.1999.01705.x.
5
The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.Bim与Mcl-1表达之间的失衡控制着人骨髓瘤细胞的存活。
Eur J Immunol. 2004 Nov;34(11):3156-64. doi: 10.1002/eji.200424981.
6
Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.促凋亡BH3肽与抗凋亡Mcl-1和A1蛋白的结合亲和力:Mcl-1和A1与六种不同BH3肽复合物的分子动力学模拟
J Mol Graph Model. 2017 May;73:115-128. doi: 10.1016/j.jmgm.2016.12.006. Epub 2017 Feb 9.
7
Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1.多发性骨髓瘤复发与核因子κB(NFκB)信号通路活性增加及促生存蛋白BCL-2家族成员BFL-1的上调有关。
Cancers (Basel). 2021 Sep 17;13(18):4668. doi: 10.3390/cancers13184668.
8
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.人促生存蛋白Bcl-xL的强效特异性肽抑制剂。
J Mol Biol. 2015 Mar 27;427(6 Pt B):1241-1253. doi: 10.1016/j.jmb.2014.09.030. Epub 2014 Nov 14.
9
Apoptotic machinery diversity in multiple myeloma molecular subtypes.多发性骨髓瘤分子亚型中的细胞凋亡机制多样性。
Front Immunol. 2013 Dec 23;4:467. doi: 10.3389/fimmu.2013.00467.
10
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.细胞周期蛋白依赖性激酶抑制剂黄酮哌醇通过转录抑制和下调Mcl-1诱导多发性骨髓瘤细胞凋亡。
Clin Cancer Res. 2002 Nov;8(11):3527-38.

引用本文的文献

1
Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers.实体癌和血液系统癌症对翻译延伸抑制剂的敏感性。
Sci Rep. 2025 Jul 1;15(1):21328. doi: 10.1038/s41598-025-06273-6.
2
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.通过凋亡调控工程化抗BCMA嵌合抗原受体T细胞以增强骨髓瘤杀伤效力。
Nat Commun. 2025 May 19;16(1):4638. doi: 10.1038/s41467-025-59818-8.
3
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention.

本文引用的文献

1
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.AMG 176,一种选择性 MCL1 抑制剂,在单独使用和与现有疗法联合使用时对血液系统癌症模型均有效。
Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25.
2
Humanized mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.人源化小鼠可实现对临床应用的 MCL-1 抑制剂的准确临床前评估。
Blood. 2018 Oct 11;132(15):1573-1583. doi: 10.1182/blood-2018-06-859405. Epub 2018 Aug 23.
3
Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK.
探索多发性骨髓瘤中维奈托克耐药性的BCL2调控及上游信号转导:治疗干预的潜在途径
Blood Cancer J. 2025 Feb 5;15(1):10. doi: 10.1038/s41408-025-01215-x.
4
A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice.一种BCL-xL/BCL-2蛋白降解靶向嵌合体(PROTAC)可有效清除肝脏中的衰老细胞,并减少小鼠中MASH驱动的肝细胞癌。
Nat Aging. 2025 Mar;5(3):386-400. doi: 10.1038/s43587-025-00811-7. Epub 2025 Jan 31.
5
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients.新诊断多发性骨髓瘤患者中Bcl-2家族蛋白的表达谱
Hemasphere. 2024 Dec 13;8(12):e70036. doi: 10.1002/hem3.70036. eCollection 2024 Dec.
6
KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis.KS18是一种Mcl-1抑制剂,它通过触发内源性凋亡来提高硼替佐米的有效性,并克服难治性多发性骨髓瘤的耐药性。
Front Pharmacol. 2024 Oct 1;15:1436786. doi: 10.3389/fphar.2024.1436786. eCollection 2024.
7
Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma.Bcl-2、Mcl-1的流式细胞术表达及其比率与多发性骨髓瘤的原发性和继发性细胞遗传学改变及其组合相关。
Ann Hematol. 2024 Dec;103(12):5473-5481. doi: 10.1007/s00277-024-06004-3. Epub 2024 Sep 12.
8
Apoptosis, a Metabolic "Head-to-Head" between Tumor and T Cells: Implications for Immunotherapy.细胞凋亡,肿瘤与 T 细胞之间的代谢“正面交锋”:对免疫治疗的影响。
Cells. 2024 May 27;13(11):924. doi: 10.3390/cells13110924.
9
Butein inhibits oral squamous cell carcinoma growth via promoting MCL-1 ubiquitination.白杨素通过促进MCL-1泛素化抑制口腔鳞状细胞癌生长。
J Cancer. 2024 Apr 15;15(10):3173-3182. doi: 10.7150/jca.94546. eCollection 2024.
10
Co-operation of MCL-1 and BCL-X anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity.MCL-1和BCL-X抗凋亡蛋白在骨髓瘤细胞的基质保护中协同作用,使其免受卡非佐米介导的细胞毒性作用。
Front Oncol. 2024 Apr 8;14:1394393. doi: 10.3389/fonc.2024.1394393. eCollection 2024.
无内在凋亡效应因子 BAX、BAK 和 BOK 时的胚胎发生和成年生活。
Cell. 2018 May 17;173(5):1217-1230.e17. doi: 10.1016/j.cell.2018.04.036.
4
Intrinsic Instability of BOK Enables Membrane Permeabilization in Apoptosis.BOK 的内在不稳定性使细胞膜在细胞凋亡中发生渗透性改变。
Cell Rep. 2018 May 15;23(7):2083-2094.e6. doi: 10.1016/j.celrep.2018.04.060.
5
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.从意义未明的单克隆丙种球蛋白血症到多发性骨髓瘤:恶性前体细胞克隆进化的范例。
Cancer Res. 2018 May 15;78(10):2449-2456. doi: 10.1158/0008-5472.CAN-17-3115. Epub 2018 Apr 27.
6
T Follicular Helper Cell-Germinal Center B Cell Interaction Strength Regulates Entry into Plasma Cell or Recycling Germinal Center Cell Fate.滤泡辅助性 T 细胞-生发中心 B 细胞相互作用强度调节进入浆细胞或再循环生发中心细胞命运。
Immunity. 2018 Apr 17;48(4):702-715.e4. doi: 10.1016/j.immuni.2018.03.027.
7
Genetics of diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的遗传学。
Blood. 2018 May 24;131(21):2307-2319. doi: 10.1182/blood-2017-11-764332. Epub 2018 Apr 17.
8
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Venetoclax 作为靶向治疗复发/难治性 t(11;14)多发性骨髓瘤的疗效。
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
9
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.硼替佐米和地塞米松联合维奈托克治疗复发/难治性多发性骨髓瘤显示出良好的疗效和可接受的安全性。
Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.
10
Evolutionary biology of high-risk multiple myeloma.高危多发性骨髓瘤的进化生物学。
Nat Rev Cancer. 2017 Aug 24;17(9):543-556. doi: 10.1038/nrc.2017.63.